| Circulating Tumor Cell cluster phenotype allows monitoring response to treatment and predicts survival A Balakrishnan, D Koppaka, A Anand, B Deb, G Grenci, V Viasnoff, ... Scientific Reports 9 (1), 7933, 2019 | 56 | 2019 |
| Bioinformatics analysis of global proteomic and phosphoproteomic data sets revealed activation of NEK2 and AURKA in cancers B Deb, P Sengupta, J Sambath, P Kumar Biomolecules 10 (2), 237, 2020 | 27 | 2020 |
| Phosphoproteomic profiling identifies aberrant activation of integrin signaling in aggressive non-type bladder carcinoma B Deb, VN Puttamallesh, K Gondkar, JP Thiery, H Gowda, P Kumar Journal of clinical medicine 8 (5), 703, 2019 | 18 | 2019 |
| Quantitative proteomics of urinary bladder cancer cell lines identify UAP1 as a potential therapeutic target VN Puttamallesh, B Deb, K Gondkar, A Jain, B Nair, A Pandey, ... Genes 11 (7), 763, 2020 | 15 | 2020 |
| N-glycoproteomic profiling reveals alteration in extracellular matrix organization in non-type bladder carcinoma B Deb, K Patel, G Sathe, P Kumar Journal of clinical medicine 8 (9), 1303, 2019 | 14 | 2019 |
| Somatic mutations profile of a young patient with metastatic urothelial carcinoma reveals mutations in genes involved in ion channels J Sharma, B Deb, IA George, S Kapil, K Coral, N Kakkar, S Pattanaik, ... Frontiers in oncology 9, 435, 2019 | 12 | 2019 |
| Urinary glycoproteomic profiling of non-muscle invasive and muscle invasive bladder carcinoma patients reveals distinct N-glycosylation pattern of CD44, MGAM, and GINM1 G Sathe, IA George, B Deb, AP Jain, K Patel, B Nayak, S Karmakar, ... Oncotarget 11 (34), 3244, 2020 | 10 | 2020 |
| Developments in the area of bladder cancer genomics and its importance in the treatment selection J Sharma, B Deb, P Kumar J Mol Oncol Res 2 (3), 58-62, 2018 | 5 | 2018 |
| Phosphoproteomics profiling to identify altered signaling pathways and kinase-targeted cancer therapies B Deb, IA George, J Sharma, P Kumar Mass Spectrometry Data Analysis in Proteomics, 241-264, 2020 | 4 | 2020 |
| Multifarious targets beyond microtubules—role of eribulin in cancer therapy P Seshadri, B Deb, P Kumar Frontiers in Bioscience-Scholar 13 (2), 157-172, 2021 | 3 | 2021 |
| The Role of Integrin α4β7 Signaling in Human Immunodeficiency Virus-1 Pathogenesis and Viral Entry in Primary CD4+ T Cells As Revealed by Comparative … N Kasarpalkar, B Deb, P Kumar, VM Bhor OMICS: A Journal of Integrative Biology 24 (7), 437-450, 2020 | 3 | 2020 |
| Targeting Gene Fusion Event s in Bladder Carcinoma J Sharma, K Gondkar, B Deb, P Kumar J Mol Genet Med 12 (361), 1747-0862.1000361, 2018 | 2 | 2018 |
| Tumor heterogeneity and phenotypic plasticity in bladder carcinoma B Deb, P Kumar Journal of the Indian Institute of Science 100 (3), 567-578, 2020 | 1 | 2020 |
| A commentary on molecular tumor board: Case 1-interplay of epidermal growth factor receptor, MET, and programmed death-ligand 1 in non-small cell lung carcinoma B Deb, P Kumar Cancer Research, Statistics, and Treatment 3 (1), 156, 2020 | 1 | 2020 |
| A commentary on outcomes with liquid biopsy to determine the epidermal growth factor receptor mutation status in poor performance status, biopsy-ineligible, advanced non-small … J Sambath, B Deb, P Kumar Cancer Research, Statistics, and Treatment 3 (1), 141-142, 2020 | 1 | 2020 |
| Biomarkers for Bladder Cancer: Present Challenge s and Recent Developments B Deb, P Kumar J Cancer Research and Treatment 6, 34-38, 2018 | 1 | 2018 |
| Biomarkers in the Tumor Stroma and Their Clinical Relevance B Deb, R Datar, S Limaye, P Kumar The Tumor Stroma, 93-122, 2022 | | 2022 |
| Tussle of tertiary testing laboratories amid the coronavirus disease-2019 crisis B Deb, R Datar, P Kumar Cancer Research, Statistics, and Treatment 3 (2), 358-359, 2020 | | 2020 |
| Bladder Carcinoma Treatment Challenges and Future Directions of Immunotherapy B Deb, P Kumar J Proteomics Bioinform 11, e38, 2018 | | 2018 |
| Identification of potential therapeutic targets for bladder cancer using phosphoproteomics approach B Deb Manipal, 0 | | |
